Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)
Open Access
- 1 June 2005
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (11), 4136-4143
- https://doi.org/10.1158/1078-0432.ccr-04-2291
Abstract
Purpose: To compare the preclinical and clinical pharmacokinetic properties of paclitaxel formulated as a Cremophor-free, albumin-bound nanoparticle (ABI-007) and formulated in Cremophor-ethanol (Taxol). Experimental Design: ABI-007 and Taxol were given i.v. to Harlan Sprague-Dawley male rats to determine pharmacokinetic and drug disposition. Paclitaxel pharmacokinetic properties also were assessed in 27 patients with advanced solid tumors who were randomly assigned to treatment with ABI-007 (260 mg/m2, 30 minutes; n = 14) or Taxol (175 mg/m2, 3 hours; n = 13), with cycles repeated every 3 weeks. Results: The volume of distribution at steady state and clearance for paclitaxel formulated as Cremophor-free nanoparticle ABI-007 were significantly greater than those for paclitaxel formulated with Cremophor (Taxol) in rats. Fecal excretion was the main elimination pathway with both formulations. Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m2 (P = 0.048) and 663.8 versus 433.4 L/m2 (P = 0.040), respectively]. Conclusions: Paclitaxel formulated as ABI-007 differs from paclitaxel formulated as Taxol, with a higher plasma clearance and a larger volume of distribution. This finding is consistent with the absence of paclitaxel-sequestering Cremophor micelles after administration of ABI-007. This unique property of ABI-007 could be important for its therapeutic effectiveness.Keywords
This publication has 15 references indexed in Scilit:
- Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patientsEuropean Journal Of Cancer, 2003
- Pharmacological Effects of Formulation VehiclesClinical Pharmacokinetics, 2003
- A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modellingCancer Chemotherapy and Pharmacology, 2002
- Cremophor ELEuropean Journal Of Cancer, 2001
- Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor ELCancer Chemotherapy and Pharmacology, 1999
- Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human fecesCancer Chemotherapy and Pharmacology, 1995
- The distribution of systemically administered [Cancer Chemotherapy and Pharmacology, 1995
- Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 miceCancer Chemotherapy and Pharmacology, 1994
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990
- Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJournal of the American Chemical Society, 1971